Table 1 Demographic characteristics of the whole CJD and np-RPD cohorts and distribution of SNAP-25 and Ng levels in the main diagnostic groups
Diagnostic group | Age at LP | Females (%) | N | CSF SNAP-25 (pg/mL) | N | CSF Ng (pg/mL) |
|---|---|---|---|---|---|---|
CJD | 66.5 ± .9.9 | 48.6 | 220 | 582 (240–1250) | 122 | 841 (411–1473) |
sCJDa | 67.5 ± 9.8 | 47.0 | 183 | 533 (249–1311) | 106 | 868 (471–1430) |
• sCJD MM(V)1 | 69.2 ± 9.5 | 35.2 | 71 | 798 (485–1559) | 31 | 1476 (1139–2527) |
• sCJD VV2 | 68.7 ± 9.8 | 41.8 | 43 | 1438 (962–2034) | 31 | 745 (384–951) |
• sCJD MV2K | 66.0 ± 9.5 | 60.3 | 53 | 230 (168–338) | 29 | 531 (320–715) |
• sCJD MM(V)2C | 62.6 ± 8.5 | 75.0 | 12 | 186 (105–403) | 11 | 1179 (695–1975) |
• sCJD MM2T | 43, 76 | 50.0 | 2 | 85.7, 348.3 | 2 | 404, 1751 |
• sCJD VV1 | 49, 64 | 50.0 | 2 | 440.5, 512.9 | 2 | 1280, 1716 |
gCJDb | 61.9 ± 10.6 | 54.0 | 37 | 662 (230–1173) | 16 | 698 (154–1708) |
• gCJD M1 | 63.3 ± 10.5 | 54.8 | 31 | 744 (344–1200) | 11 | 983 (355–1718) |
• gCJD M “i “ | 49, 68 | 50.0 | 2 | 107.2, 121.7 | 1 | -, 157 |
• gCJD M2T | 45, 68, 49 | 33.3 | 3 | 37.2, 52.5, 75.3 | 3 | 14, 84, 153 |
• gCJD V1 | 49 | 100.0 | 1 | 334.3 | 1 | 1785 |
np-RPD | 70.9 ± 11.3 | 52.1 | 213 | 115 (78–157) | 93 | 390 (260–766) |
Non-neurodegenerative | 67.4 ± 11.7 | 45.9 | 98 | 114 (70–162) | 43 | 416 (228–945) |
rp-ND | 73.1 ± 9.9 | 59.4 | 101 | 114 (81–156) | 45 | 354 (273–646) |
Mixed | 74.0 ± 6.9 | 42.8 | 14 | 125 (70–146) | 5 | 787 (355–956) |